According to the bomb lawsuit, the Imclone Insider Trading scandal, which landed in prison for the Imclone Insider Trading scandal, which landed in prison 20 years ago through Martha Stewart’s time, allegedly tested illegal “swolf drug” treatments in children with epilepsy.
The non-doctor Waxal imported veterinary medicine along with other “unapproved materials” from Colombia to treat a “severely ill” child whose mother worked for the company, according to a complaint filed this week in federal court in Manhattan.
Waksal is said to have monitored the child’s response to the drug in order to develop a similar product from his previous company, Equilibre Biopharmaceuticals.
The alleged administration took place over a “term of several months” and was revealed when the equilibrium whistleblower exposed the scheme in 2022, Neil Brickman, a counsel representing the equilibrium, told the Post.
Brickman said the child’s health is unknown.
A whistleblower, who was an employee at the time, accused Waksal of creating a sexual harassment and a hostile work environment, the lawsuit has not provided details.
Vaxal, now 77, is famously selling his shares of ImClone in 2001 after learning that the FDA would not approve the company’s cancer drugs. He served five years in prison for securities fraud, and Stewart served five months lying about why he sold Imclone stock before they tanked.
Waksal declined to comment when he reached this week, but after learning about the investigation he posted a screenshot of a text exchange in 2022 claiming it was between himself and the mother of a child.
“We deal with dying children and hope they understand that you are kind and caring,” the mother is said to have written. “I fully understand the risks.”
This post could not be independently confirmed texts that appear to be from mothers, which spanned the period from May 2022 to December 2022.
“Sam knew the drug wasn’t approved. [by the FDA] Brickman said. “He did that anyway.”
“When he found out he was doing this, he stopped treating his child, not because the child got sick or better from the administration,” Brickman added.
Waksal is accused of obstructing the investigation by placing her mother on administrative leave from work in equilibrium to prevent her from speaking to investigators, according to the complaint.
According to the complaint, another witness was also provided $100,000 in company funding to influence participation in the investigation.
The allegations sparked an investigation conducted by two external law firms, resulting in Waksal’s forced resignation in 2022 as chairman and chief executive of Equilibre, which he founded just two years ago.
Equilbre notified the FDA of the incident, according to the lawsuit.
“As far as we know, there was no official responsibilities,” Brickman said.
The lawsuit accused Waksal, the three equilibrium supervision and Graviton, owner of another biotech company Waksal, as defendants, of “recklessly ignoring legal, ethical and corporate governance standards.”
Board members, including those who gave drug preparations to the sick dog who died the following day, are allegedly conspired with the scheme, according to the submission.
After Waksal was removed from the equilibrium, he began to “scatter” the company. The complaint has led investors to Graviton and “convert” equilibrium research, intellectual property and other assets to Graviton.
Equilibre filed for bankruptcy protection in 2023, with a US trustee representing our creditors filed a complaint, seeking at least $150 million.
A spokesman for Graviton said, “Graviton Bioscience conducts innovative and truly groundbreaking scientific research in multiple disease areas that can dramatically improve the lives of patients suffering from cancer, Alzheimer’s disease, autoimmune disorders, and multiple other incidents.
“With such a strong outlook, it’s probably not surprising that Graviton is the target. The company is aware of the filings we know are no merit and will begin to defend vigorously.”
Graviton received a private investment from Sanofi last year. Sanofi acquired Kadmon, another company founded in 2021 for $2 billion.
